Cancer treatment survival rate improver
Kefir-based agents enhance cancer treatment survival rates by improving the efficacy of chemotherapy and radiotherapy, offering a safe and effective means to increase patient longevity.
Patent Information
- Application Number
- JP2018547795
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2016-10-27
- Filing Date
- 2017-10-27
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2037-10-27
Smart Images

Figure 0007577262000009 
Figure 0007577262000001 
Figure 0007577262000002
Abstract
Description
[Technical field]
[0001] The present invention relates to an agent for improving survival rate of cancer treatment. [Background technology]
[0002] Chemotherapy and radiation therapy are important means of treating cancer. Although they often cause serious side effects, they are still used after weighing up the side effects because they are powerful means of eliminating cancer cells.
[0003] The survival rate is an important indicator for evaluating the results of cancer treatment. Since the long-term survival of patients is important in cancer treatment, there is a constant demand for better cancer treatment methods that use the survival rate as an indicator, apart from direct observations and test values regarding the shrinkage and disappearance of tumor tissue and removal of cancer cells immediately after treatment.
[0004] Kefir is a fermented milk originating from the Caucasus region of Russia, and is produced by fermenting animal milk such as cow's milk using kefir grains (kefir grains, kefir bacteria) originating from the Caucasus region as a starter. Kefir grains themselves behave as if they were a living organism, but academically, they are a natural symbiotic organism of various microorganisms, including Lactobacillus kefiri, and one or more microorganisms of the genera Leuconostoc, Lactococcus, and Acetobacter, as well as lactose-fermenting yeasts (e.g., Kluyveromyces marxianus) and non-lactose-fermenting yeasts (e.g., Saccharomyces unisporus, Saccharomyces cerevisiae, Saccharomyces exiguus). In addition to being delicious as a fermented milk, kefir has been noted to have various health-maintaining and promoting functions, and is becoming popular as a healthy food.
[0005] In order to make the most of the excellent properties of kefir, attempts have been made to add various food ingredients to kefir to create foods with even better health maintenance and promotion functions. For example, Patent Document 1 (WO2002 / 076240) discloses a food product in which nattokinase has been added to kefir. It has also been reported that kefir has the effect of preventing and improving liver dysfunction (Patent Document 2: Patent No. 5823695). [Prior art documents] [Patent documents]
[0006] [Patent Document 1] International Publication No. 2002 / 076240 [Patent Document 2] Patent No. 5823695 Summary of the Invention [Problem to be solved by the invention]
[0007] Under these circumstances, there has been a demand for means for improving the survival rate of cancer treatments, particularly chemotherapy and radiation therapy, whose clinical effectiveness has been confirmed.
[0008] Therefore, an object of the present invention is to provide a means for improving the survival rate of cancer treatments, the clinical effectiveness of which has been confirmed, particularly chemotherapy and radiotherapy. [Means for solving the problem]
[0009] The present inventor has been involved in clinical cancer treatment and has been conducting intensive research into the outcomes of cancer treatment for many years. He has discovered that there is a statistically significant relationship between the administration of kefir and the effect of improving survival rates, and thus arrived at the present invention.
[0010] Therefore, the present invention includes the following (1) and the following. (1) An agent for improving survival rate of cancer treatment, comprising kefir as an active ingredient. (2) The survival rate improving agent according to (1), wherein the cancer treatment is chemotherapy and / or radiation therapy. (3) The survival rate improving agent according to any one of (1) to (2), wherein the cancer is oral cancer. (4) The survival rate improving agent according to any one of (1) to (3), wherein the chemotherapy is superselective intra-arterial chemotherapy. (5) The survival rate improving agent according to any one of (1) to (4), wherein the survival rate after cancer treatment is the survival rate 2 years, 3 years, 4 years, or 5 years after the cancer treatment. (6) A pharmaceutical composition for improving survival rate of cancer treatment, comprising kefir as an active ingredient. (7) A food composition for improving survival rate of cancer treatment, comprising kefir as an active ingredient.
[0011] The present invention further includes the following (11) and the following: (11) administering kefir to the patient during the treatment period of the cancer treatment; 23. A method for improving cancer treatment survival, comprising: (12) Use of kefir for the manufacture of a pharmaceutical composition for improving survival rate from cancer treatment or a food composition for improving survival rate from cancer treatment. Effect of the Invention
[0012] According to the present invention, the survival rate of cancer treatment, particularly the survival rate of chemotherapy and / or radiation therapy, can be improved. Since the improvement of survival rate is one of the major objectives of cancer treatment, the present invention, which can improve the survival rate by extremely simple administration without interfering with cancer treatment, is of great significance.
[0013] Since the kefir according to the present invention has been consumed by humans for many years, it does not have side effects or safety concerns and can be administered continuously for a long period of time without worry. Since chemotherapy and / or radiotherapy for cancer treatment often last for a long period of time, such as several weeks to several months, it is a great advantage of the present invention that it can be administered continuously for a long period of time without worry.
[0014] In addition, since the kefir according to the present invention has been consumed by humans for many years, it has excellent palatability and is easy to take. When chemotherapy and / or radiation therapy are administered for cancer treatment, nausea and the like often occur as side effects, so the excellent palatability and ease of taking are major advantages of the present invention. [Brief description of the drawings]
[0015] [Figure 1] FIG. 1 shows survival rates after cancer treatment. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0016] The present invention will be described in detail below with reference to specific embodiments, but the present invention is not limited to the specific embodiments described below.
[0017] [Cancer treatment survival rate improvement agent] The agent for improving survival rate from cancer treatment of the present invention contains kefir as an active ingredient.
[0018] The kefir used in the present invention can be produced based on a known production method. Kefir can be produced by fermenting animal milk, i.e., milk of cows, horses, sheep, goats, etc., but preferably, it can be produced by adding kefir grains to cow's milk and fermenting it. Furthermore, soy milk kefir and vegetable kefir produced by adding kefir grains to soy milk or other plant-derived raw materials as the starting material and fermenting it can also be used as the kefir used in the present invention. For the production method of these, for example, JP-A-62-83842 and JP-A-2006-75176 can be referred to. The kefir used in the present invention includes liquid and fluid kefir, as well as solids such as freeze-dried products thereof, which can be in the form of powder, granules, capsules containing these, etc., and also includes those obtained by formulation by known methods.
[0019] Suitable kefir for use include commercially available products such as NKG Kefir-D (manufactured by Nippon Kefir Co., Ltd.), NKG Kefir-P (manufactured by Nippon Kefir Co., Ltd.), and NKG Soymilk Kefir-SD (manufactured by Nippon Kefir Co., Ltd.).
[0020] The agent for improving survival rate of cancer treatment of the present invention contains kefir as an active ingredient. The agent for improving survival rate of cancer treatment of the present invention may be kefir itself in various forms, or may contain ingredients other than kefir. The agent for improving survival rate of cancer treatment of the present invention may be a composition containing kefir as an active ingredient, and may be, for example, a pharmaceutical composition for improving survival rate of cancer treatment and a food composition for improving survival rate of cancer treatment.
[0021] The cancer treatment survival rate improver of the present invention can be in various forms suitable for the administration method. The cancer treatment survival rate improver of the present invention can be in the form of, for example, capsules, tablets, granules, powders, syrups, lozenges, sprays, emulsions, suppositories, injections, ointments, tapes, etc. When administered orally, it can be processed into tablets, capsules, lozenges, syrups, granules, powders, etc. and taken orally. The administration of the cancer treatment survival rate improver of the present invention can be, for example, oral administration or parenteral administration, preferably oral administration or enteral administration, and particularly preferably oral administration. The cancer treatment survival rate improver of the present invention can also be administered by mixing it with food, drink, feed, etc.
[0022] The cancer treatment survival rate improver of the present invention can be in the form of food and drink. That is, the present invention also relates to functional food for improving cancer treatment survival rate. A tablet-shaped supplement can be exemplified as a suitable form when made into functional food. This allows accurate understanding of the intake amount of active ingredients. Furthermore, the cancer treatment survival rate improver of the present invention can be in the form of a food additive.
[0023] The cancer treatment survival rate improver of the present invention can be produced, for example, by formulating kefir with any additive such as a pharmaceutically acceptable excipient. When formulating, the content of kefir in the formulation is usually 0.01 to 50% by mass, preferably 0.1 to 25.0% by mass. When formulating, additives such as pharmaceutically acceptable known excipients, binders, disintegrants, lubricants, stabilizers, flavorings, diluents, and solvents for injections can be used. When formulating, known manufacturing methods can be used. In addition, the cancer treatment survival rate improver of the present invention can be added with auxiliary ingredients commonly used in the fields of medicine and food, such as lactose, sucrose, liquid sugar, honey, magnesium stearate, hydroxypropyl cellulose, various vitamins, citric acid, malic acid, amino acids, flavors, inorganic salts, etc., as necessary.
[0024] [Dosage] The dosage and frequency of administration of kefir, which is the active ingredient of the present invention, vary depending on the administration method, treatment period, age, body weight, etc., but the dosage can be appropriately selected from the range of 1 mg to 50 g per day for adults, and the frequency of administration can be appropriately selected from the range of once to several times per day. Since kefir has been consumed as a traditional food for many historical years, there is no need to worry about side effects and it is highly safe, so there is no problem even if the dosage is even higher.
[0025] [Time of administration] The administration of the cancer treatment survival rate improving agent of the present invention is usually performed at least one day, preferably at least two days, more preferably at least three days, and even more preferably at least one week before the start of chemotherapy or radiotherapy. Since kefir has been consumed as a traditional food for many historical years, there is no problem no matter how long it is administered before the start of chemotherapy or radiotherapy. In a preferred embodiment, it is administered during the period during which chemotherapy or radiotherapy is being performed. In addition, there is no problem no matter if kefir is continued to be administered after the end of the chemotherapy or radiotherapy treatment period.
[0026] [Improving cancer treatment survival rate] In the present invention, the improvement of survival rate from cancer treatment means that the survival rate of cancer patients who have undergone cancer treatment, particularly chemotherapy and / or radiation therapy, after a certain number of days or years from the date of cancer diagnosis is improved. Such a certain number of years can be, for example, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, or 10 years.
[0027] It is unclear by what mechanism kefir, the active ingredient of the present invention, improves the survival rate of cancer treatment. However, since kefir shows such effects when administered orally, i.e., systemically, it is believed that the effect of improving the survival rate of cancer treatment is not limited to oral cancer, but also shows a similar effect of improving the survival rate of cancer treatment for cancers at any site in the body.
[0028] The effect of kefir, which is the active ingredient according to the present invention, in improving the survival rate of cancer treatment has been confirmed to be statistically significant by clinical trials, particularly in the survival rate of cancer patients undergoing chemotherapy and / or radiation therapy in the treatment of oral cancer, but it is also considered to be effective in improving the survival rate of other cancer treatments. Chemotherapy includes all types of chemotherapy in which anticancer drugs are administered, and the administration method also includes all types of administration methods. Examples of chemotherapy include systemic chemotherapy and superselective intra-arterial chemotherapy. Radiation therapy includes all types of radiation therapy. EXAMPLES
[0029] The present invention will be described in detail below with reference to examples, but the present invention is not limited to the examples illustrated below.
[0030] [Clinical Trials] The effect of kefir on the survival rate of cancer patients undergoing cancer treatment has been confirmed in clinical trials (follow-up studies) on cancer patients, including:
[0031] [subject] [Group A (6 patients A to F)] 1. Patient A: Female, 70s. Squamous cell carcinoma of the mandibular gingiva. Postoperative external radiation therapy (55 Gy). 2. Patient B: Male, 50s, squamous cell carcinoma of the tongue, postoperative external radiation (50Gy) 3. Patient C: Female, 80s. Squamous cell carcinoma of the mandibular gingiva. Radical external beam radiation (66 Gy), chemotherapy (UFT 300 mg / day). 4. Patient D, male, 50s, squamous cell carcinoma of the mandibular gingiva, preoperative external radiation (40Gy), chemotherapy (CDDP 120mg, 5-FU 2250mg) 5. Patient E, female, 70s, squamous cell carcinoma of the mandibular gingiva, curative external beam radiation (30Gy), interstitial beam radiation (60Gy), chemotherapy (TS-1 100mg / day) 6. Patient F, female, 70s, squamous cell carcinoma of the buccal mucosa, curative external beam radiation (70Gy)
[0032] [Group B (17 patients G~W)] 1. Patient G, male, 60s, squamous cell carcinoma of the floor of the mouth, postoperative external radiation (50Gy) 2. Patient H, male, 50s, squamous cell carcinoma of the floor of the mouth, preoperative external radiation therapy (40Gy) 3. Patient I: Male, 70s. Squamous cell carcinoma of the mandibular gingiva. Radical external beam radiation (66Gy), chemotherapy (TS-1 80mg / day). 4. Patient J, male, 60s, squamous cell carcinoma of the tongue, curative external beam radiation (30Gy), interstitial beam radiation (60Gy), chemotherapy (TS-1 80mg / day) 5. Patient K, male, 30s, squamous cell carcinoma of the tongue, curative external beam radiation (30 Gy), interstitial beam radiation (60 Gy), chemotherapy (CDDP 150 mg) 6. Patient L, male, 60s, squamous cell carcinoma of the floor of the mouth, curative external beam radiation (30Gy), interstitial beam radiation (60Gy), chemotherapy (CDDP 130mg + 5-FU 4000mg) 7. Patient M, male, 60s, squamous cell carcinoma of the tongue, curative external beam radiation (70Gy) 8. Patient N, female, 70s, squamous cell carcinoma of the mandibular gingiva, postoperative external radiation (60Gy), chemotherapy (CDDP 100 mg + 5-FU 3000 mg) 9. Patient O: Female, 70s, squamous cell carcinoma of the buccal mucosa, curative external beam radiation (66 Gy), chemotherapy (UFT 300 mg / day) 10. Patient P, male, 90s, squamous cell carcinoma of the mandibular gingiva, curative external beam radiation (70Gy), chemotherapy (UFT 300mg / day) 11. Patient Q: Male, 80s. Squamous cell carcinoma of the tongue. Curative external beam radiation (66Gy). 12. Patient R, male, 50s, squamous cell carcinoma of the floor of the mouth, preoperative external radiation therapy (40Gy) 13. Patient S, male, 50s, squamous cell carcinoma of the tongue, postoperative external beam radiation (60Gy), chemotherapy (CDDP 100 mg + 5-FU 3000 mg) 14. Patient T, male, 70s, squamous cell carcinoma of the mandibular gingiva, preoperative external radiation therapy (40Gy) 15. Patient U, male, 60s, squamous cell carcinoma of the mandibular gingiva, curative external beam radiation (60Gy), chemotherapy (CDDP 80mg + 5-FU 3000mg) 16. Patient V, male, 80s, squamous cell carcinoma of the buccal mucosa, curative external beam radiation (70Gy) 17. Patient W, male, 70s, squamous cell carcinoma of the mandibular gingiva, curative external beam radiation (70Gy)
[0033] [Patient background] The patient background is summarized in Table 1 below. All chemotherapy was systemic chemotherapy. Group A was the group administered kefir, and Group B was the group not administered kefir.
[0034] [Table 1]
[0035] [Oral cancer stage classification] The stage classification of oral cancer is summarized in Table 2 below. This stage classification is as shown in Table 3 below and is based on the stage classification of malignant tumors by the Union for International Cancer Control (UICC, 2010, 7th edition).
[0036] [Table 2]
[0037] [Table 3]
[0038] In the stage classification in Table 3, they are as follows: [T-Primary tumor] TX: Primary tumor cannot be assessed T0: No evidence of primary tumor Tis: Carcinoma in situ T1: Tumor 2 cm or less in greatest dimension T2: Tumor >2 cm but <4 cm in greatest dimension T3: Tumor larger than 4 cm in greatest dimension T4a: Lip: Tumor invades the bone marrow, inferior alveolar nerve, floor of the mouth, skin (chin or nose) T4a: Tumor invades the oral cavity, bone marrow, deep / extrinsic tongue muscles (genioglossus, hyoglossus, palatoglossus, styloglossus), maxillary sinus, or facial skin. T4b: Lips and oral cavity: Tumor invades the masseter space, pterygoid process, or skull base, or circumferentially surrounds the internal carotid artery (Note: The primary lesion is the gingiva, and cases with superficial erosion only in the bone and alveolar cavity are not considered T4.)
[0039] [N-Regional lymph nodes] NX: Regional lymph node metastasis cannot be assessed N0: No regional lymph node metastasis N1: A single ipsilateral lymph node metastasis measuring 3 cm or less in greatest dimension N2: Metastasis in a single ipsilateral lymph node >3 cm but ≤6 cm in greatest dimension, or metastasis in multiple ipsilateral lymph nodes ≤6 cm in greatest dimension, or metastasis in bilateral or contralateral lymph nodes ≤6 cm in greatest dimension N2a: Metastasis in a single ipsilateral lymph node >3 cm but ≤6 cm in greatest dimension N2b: Multiple ipsilateral lymph node metastases, 6 cm or less in greatest dimension N2c: Metastasis in bilateral or contralateral lymph nodes measuring 6 cm or less in greatest dimension N3: Lymph node metastasis greater than 6 cm in greatest dimension (Note: The median lymph nodes are the ipsilateral lymph nodes.)
[0040] [M-Distant metastasis] MX: Distant metastasis cannot be assessed M0: No distant metastasis M1: Distant metastasis
[0041] [Administration of kefir] Kefir was administered by taking two sachets of a granular preparation of dried kefir powder once after each meal (six sachets per day) during the treatment period of radiotherapy and / or chemotherapy. Each sachet contained 4g of the granular preparation, equivalent to 25mg of dried kefir per sachet.
[0042] [Analysis method] Among oral cancer patients (2006 to 2010) who underwent radiotherapy and chemotherapy at the Department of Oral and Maxillofacial Surgery, Hiroshima University Hospital, the prognosis (survival rate) between two groups was examined using the Kaplan-Meier method: a group of six patients (kefir administration group) who agreed to take kefir during the treatment period, and a group of 17 patients (control group) who underwent similar treatment during the same period. GraphPad Prism Ver 4.0 for Macintosh was used as the statistical processing software.
[0043] [Outcome] The outcomes are summarized in Table 4 below. Death from primary disease refers to death from an illness thought to be caused by the cancer that was the subject of cancer treatment, while death from other diseases refers to death from an illness other than the primary disease.
[0044] [Table 4]
[0045] [Number of days to survive] The survival times of the 6 patients in Group A (patients A-F, radiotherapy + chemotherapy + kefir administration) are summarized in Table 5. The survival times of the 17 patients in Group B (patients G-W, radiotherapy + chemotherapy + kefir non-administration) are summarized in Table 6. In the table, if the patient was alive at the time of the survey, the survival times are marked with "+α".
[0046] [Table 5]
[0047] [Table 6]
[0048] [Kaplan-Meier survival curve] The log-rank test revealed a significant difference in survival rate between groups A and B with a P value of 0.0369 (risk ratio of 5% or less). The results are shown in Figure 1.
[0049] In Figure 1, the horizontal axis is time (days) and the vertical axis is survival rate (%). Of the two survival curves in Figure 1, the upper survival curve is the kefir-administered group (Kefia(+)) (Group A), and the lower survival curve is the kefir-unadministered group (Kefia(-)) (Group B). The conditions for this test are summarized in Table 7 below.
[0050] [Table 7]
[0051] These results demonstrated that the kefir-administered group (Group A) had a significantly higher survival rate than the non-administered group (Group B) (P value 0.0369).
[0052] [Survival rate after a given number of years] The survival rates and survival numbers after 1 to 5 years for Groups A and B shown in Figure 1 are summarized again in Table 8 below. [Table 8]
[0053] [Summary of results] 1. It was found that the survival rate of cancer treatment was significantly improved in the kefir-administered group (Group A) at 1, 2, 3, and 4 years after cancer treatment compared to the control group (Group B) (Group B). It was also found that the survival rate of cancer treatment was significantly improved at 5 years after cancer treatment compared to the control group (Group B) (Group B), and was also improved at 6 and 7 years after cancer treatment. 2. No allergies or side effects thought to be due to kefir were observed in the group of patients who were administered kefir. In addition, compliance with the oral administration instructions was good.
[0054] Thus, oral administration of kefir was effective in improving the survival rate of cancer treatment. Furthermore, no side effects were observed, it was highly safe, and none of the patients discontinued taking it, making it easy to take. [Industrial Applicability]
[0055] The agent for improving survival rate from cancer treatment according to the present invention can improve the survival rate from cancer treatment, particularly the survival rate from chemotherapy and radiotherapy. The present invention provides, for the first time, an agent for improving survival rate from cancer treatment that has a clinically confirmed and statistically significant effect. The present invention is an industrially useful invention.
Claims
1. A cancer treatment survival rate improving agent for oral administration, comprising kefir as an active ingredient, the cancer treatment survival rate is the survival rate 3 years, 4 years, or 5 years after the cancer treatment; 2. A cancer treatment survival rate improving agent for oral administration, wherein the cancer treatment is radiation therapy or chemotherapy and radiation therapy.
2. The survival rate improving agent of claim 1, wherein the cancer is oral cancer.
3. The survival rate improving agent according to any one of claims 1 to 2, wherein the chemotherapy is superselective intra-arterial chemotherapy.
4. A pharmaceutical composition for improving survival rate of cancer treatment for oral administration, comprising kefir as an active ingredient, the cancer treatment survival rate is the survival rate 3 years, 4 years, or 5 years after the cancer treatment; A pharmaceutical composition for improving survival rate of cancer treatment for oral administration, wherein the cancer treatment is radiation therapy or chemotherapy and radiation therapy.
5. A food composition for improving survival rate of cancer treatment, comprising kefir as an active ingredient, the cancer treatment survival rate is the survival rate 3 years, 4 years, or 5 years after the cancer treatment; A food composition for improving survival rate after treatment, wherein the cancer treatment is radiation therapy or chemotherapy and radiation therapy.
6. 1. Use of kefir for the manufacture of a pharmaceutical composition for improving survival rate from cancer treatment or a food composition for improving survival rate from cancer treatment for oral administration, comprising: the cancer treatment survival rate is the survival rate 3 years, 4 years, or 5 years after the cancer treatment; The use wherein the cancer treatment is radiation therapy or chemotherapy and radiation therapy.
Citation Information
Patent Citations
6-triphenylmethylamino-2,2-dimethyl-penam compound
JP1983023695A
Health foods containing natto kinase and fermented milk porducts
WO2002076240A1
Prophylactic agent for hepatic function disorders
WO2010064434A1
